Implications of Hematopoietic Stem Cells Heterogeneity for Gene Therapies

Overview

Journal Gene Ther

Date 2021 Feb 16

PMID 33589780

Citations 9

Authors

Jeremy Epah

Richard Schafer

Affiliations

Soon will be listed here.

Abstract

Hematopoietic stem cell transplantation (HSCT) is the therapeutic concept to cure the blood/immune system of patients suffering from malignancies, immunodeficiencies, red blood cell disorders, and inherited bone marrow failure syndromes. Yet, allogeneic HSCT bear considerable risks for the patient such as non-engraftment, or graft-versus host disease. Transplanting gene modified autologous HSCs is a promising approach not only for inherited blood/immune cell diseases, but also for the acquired immunodeficiency syndrome. However, there is emerging evidence for substantial heterogeneity of HSCs in situ as well as ex vivo that is also observed after HSCT. Thus, HSC gene modification concepts are suggested to consider that different blood disorders affect specific hematopoietic cell types. We will discuss the relevance of HSC heterogeneity for the development and manufacture of gene therapies and in exemplary diseases with a specific emphasis on the key target HSC types myeloid-biased, lymphoid-biased, and balanced HSCs.

Citing Articles

Transcriptomic Profile of LinSca1c-kit (LSK) cells in db/db mice with long-standing diabetes.

Mahajan N, Luo Q, Abhyankar S, Bhatwadekar A BMC Genomics. 2024; 25(1):782.

PMID: 39134978 PMC: 11318115. DOI: 10.1186/s12864-024-10679-3.

Combination of CD49b and CD229 Reveals a Subset of Multipotent Progenitors With Short-Term Activity Within the Hematopoietic Stem Cell Compartment.

Somuncular E, Su T, Dumral O, Johansson A, Luc S Stem Cells Transl Med. 2023; 12(11):720-726.

PMID: 37706539 PMC: 10630077. DOI: 10.1093/stcltm/szad057.

Unravelling human hematopoietic progenitor cell diversity through association with intrinsic regulatory factors.

Favaro P, Glass D, Borges L, Baskar R, Reynolds W, Ho D bioRxiv. 2023; .

PMID: 37693547 PMC: 10491219. DOI: 10.1101/2023.08.30.555623.

Haematopoietic stem and progenitor cell heterogeneity is inherited from the embryonic endothelium.

Ghersi J, Baldissera G, Hintzen J, Luff S, Cheng S, Xia I Nat Cell Biol. 2023; 25(8):1135-1145.

PMID: 37460694 PMC: 10415179. DOI: 10.1038/s41556-023-01187-9.

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.

Lamers-Kok N, Panella D, Georgoudaki A, Liu H, Ozkazanc D, Kucerova L J Hematol Oncol. 2022; 15(1):164.

PMID: 36348457 PMC: 9644572. DOI: 10.1186/s13045-022-01382-5.

References

Muul L, Tuschong L, Soenen S, Jagadeesh G, Jay Ramsey W, Long Z . Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2002; 101(7):2563-9. DOI: 10.1182/blood-2002-09-2800. View

Blaese R, Culver K, Miller A, Carter C, Fleisher T, Clerici M . T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science. 1995; 270(5235):475-80. DOI: 10.1126/science.270.5235.475. View

Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang G, Berry C . Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010; 363(4):355-64. PMC: 2957288. DOI: 10.1056/NEJMoa1000164. View

Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese M, Baricordi C . Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013; 341(6148):1233151. PMC: 4375961. DOI: 10.1126/science.1233151. View

Thompson A, Walters M, Kwiatkowski J, Rasko J, Ribeil J, Hongeng S . Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2018; 378(16):1479-1493. DOI: 10.1056/NEJMoa1705342. View

Ribeil J, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E . Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med. 2017; 376(9):848-855. DOI: 10.1056/NEJMoa1609677. View

Hock R, Miller A, Osborne W . Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood. 1989; 74(2):876-81. View

Sureda A, Bader P, Cesaro S, Dreger P, Duarte R, Dufour C . Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015; 50(8):1037-56. DOI: 10.1038/bmt.2015.6. View

Zeng Y, He J, Bai Z, Li Z, Gong Y, Liu C . Tracing the first hematopoietic stem cell generation in human embryo by single-cell RNA sequencing. Cell Res. 2019; 29(11):881-894. PMC: 6888893. DOI: 10.1038/s41422-019-0228-6. View

10.

Giladi A, Paul F, Herzog Y, Lubling Y, Weiner A, Yofe I . Single-cell characterization of haematopoietic progenitors and their trajectories in homeostasis and perturbed haematopoiesis. Nat Cell Biol. 2018; 20(7):836-846. DOI: 10.1038/s41556-018-0121-4. View

11.

Oguro H, Ding L, Morrison S . SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell. 2013; 13(1):102-16. PMC: 3736853. DOI: 10.1016/j.stem.2013.05.014. View

12.

Wilson A, Laurenti E, Oser G, van der Wath R, Blanco-Bose W, Jaworski M . Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008; 135(6):1118-29. DOI: 10.1016/j.cell.2008.10.048. View

13.

Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka D, Reyes A, Wang Q . Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014; 15(4):507-522. DOI: 10.1016/j.stem.2014.07.005. View

14.

Pietras E, Reynaud D, Kang Y, Carlin D, Calero-Nieto F, Leavitt A . Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions. Cell Stem Cell. 2015; 17(1):35-46. PMC: 4542150. DOI: 10.1016/j.stem.2015.05.003. View

15.

Thomas E . A history of haemopoietic cell transplantation. Br J Haematol. 1999; 105(2):330-9. DOI: 10.1111/j.1365-2141.1999.01337.x. View

16.

Wang X, Riviere I . Genetic Engineering and Manufacturing of Hematopoietic Stem Cells. Mol Ther Methods Clin Dev. 2017; 5:96-105. PMC: 5415326. DOI: 10.1016/j.omtm.2017.03.003. View

17.

Cavazzana M, Bushman F, Miccio A, Andre-Schmutz I, Six E . Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov. 2019; 18(6):447-462. DOI: 10.1038/s41573-019-0020-9. View

18.

Morgan R, Gray D, Lomova A, Kohn D . Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. Cell Stem Cell. 2017; 21(5):574-590. PMC: 6039108. DOI: 10.1016/j.stem.2017.10.010. View

19.

Flowers M, Inamoto Y, Carpenter P, Lee S, Kiem H, Petersdorf E . Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011; 117(11):3214-9. PMC: 3062319. DOI: 10.1182/blood-2010-08-302109. View

20.

Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S . Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia. 1999; 13(12):2059, 2060-9. View